New drug improves motor milestones and survival in infants with spinal muscular atrophy

New drug improves motor milestones and survival in infants with spinal muscular atrophy
Image: Intellect (generated)

In short: A phase 3 clinical trial of 73 infants with spinal muscular atrophy found that the drug nusinersen significantly improved motor function and survival rates. The study observed that infants receiving the treatment were much more likely to reach motor milestones and stay alive without requiring permanent ventilation compared to those receiving a sham control.

Spinal muscular atrophy is a genetic disorder caused by a lack of a specific protein. Nusinersen works by modifying RNA to increase the production of this protein. The researchers used a randomized, double-blind, sham-controlled trial to measure how the drug affected infants' development and survival.

The study noted that infants who began treatment earlier in the disease's progression saw greater benefits. A limitation of the study is that it is a clinical trial focused on specific primary endpoints, and while it shows significant improvement, the results are specific to this patient population.

Why it matters: Early genetic intervention can significantly improve life expectancy and physical development for infants with specific neuromuscular disorders.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/science-research-new-drug-improves-motor-milestones-and-survival-in-infants-w.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…